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Abstract
Background: Data on the methods used for microbiological diagnosis of hospital-acquired pneumonia (HAP) are
mainly extrapolated from ventilator-associated pneumonia. HAP poses additional challenges for respiratory sampling,
and the utility of sputum or distal sampling in HAP has not been comprehensively evaluated, particularly in HAP
admitted to the ICU.
Methods: We analyzed 200 patients with HAP from six ICUs in a teaching hospital in Barcelona, Spain. The respiratory
sampling methods used were divided into non-invasive [sputum and endotracheal aspirate (EAT)] and invasive [fiberoptic-
bronchoscopy aspirate (FBAS), and bronchoalveolar lavage (BAL)].
Results: A median of three diagnostic methods were applied [range 2–4]. At least one respiratory sampling method was
applied in 93% of patients, and two or more were applied in 40%. Microbiological diagnosis was achieved in 99 (50%)
patients, 69 (70%) by only one method (42% FBAS, 23% EAT, 15% sputum, 9% BAL, 7% blood culture, and 4% urinary
antigen). Seventy-eight (39%) patients underwent a fiberoptic-bronchoscopy when not receiving mechanical ventilation.
Higher rates of microbiological diagnosis were observed in the invasive group (56 vs. 39%, p= 0.018). Patients with
microbiological diagnosis more frequently presented changes in their empirical antibiotic scheme, mainly de-escalation.
Conclusions: A comprehensive approach might be undertaken for microbiological diagnosis in critically ill nonventilated
HAP. Sputum sampling determined one third of microbiological diagnosis in HAP patients who were not subsequently
intubated. Invasive methods were associated with higher rates of microbiological diagnosis.
Keywords: Hospital-acquired pneumonia, Microbiological diagnosis, Diagnostic methods, Hospital infections,
Bronchoalveolar lavage
Introduction
Hospital-acquired pneumonia (HAP) is a frequent event
during an intensive care unit (ICU) stay and is character-
ized by a pneumonia acquired during hospitalization, in
patients without invasive mechanical ventilation [1–3].
Despite improved prevention measures, antimicrobial
therapy, and supportive care, it remains an important
cause of morbidity and mortality [1–3]. HAP is the lead-
ing cause of death among hospital-acquired infections,
with estimates of its associated mortality ranging from 20
to 50% [2, 4–6].
Microbiological diagnosis is fundamental for guiding
HAP treatment, allowing a targeted, effective antibiotic
choice, and reducing the associated impact of ineffective
empiric antibiotic regimens or the unnecessary use of
broad-spectrum antibiotics [1]. Yet the current under-
standing of HAP pathogens is based mainly on data de-
rived from ventilator-associated pneumonia (VAP) [7–15].
Although some studies have reported the pathogens in
HAP that occur outside the ICU [16–18], there is no sys-
tematic description of the diagnostic approaches that
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should be used to efficiently obtain an microbiological
diagnosis in HAP, mainly when critically ill [1].
In comparison with VAP, HAP poses additional chal-
lenges for respiratory sampling and, thus, for obtaining
microbiological diagnosis. The utility of sputum cultures
or distal sampling for HAP has not been comprehen-
sively evaluated [1]. The recent guidelines for HAP/VAP
recognized that for some patients, whom non-invasively
sampling is not possible, invasive sampling is an option
[1, 3]; however, the literature is scarce to support one
method over the other in HAP. In this study, we aimed
to describe the diagnostic approaches used in a cohort




We conducted a retrospective analysis of a prospective co-
hort including patients from six medical and surgical ICUs
at an 800-bed teaching hospital in Spain. Patients older
than 18 years admitted to these ICUs for 48 h or more
with clinical suspicion of HAP or VAP were prospectively
and consecutively included. Patients with severe immuno-
suppression (neutropenia after chemotherapy or
hematopoietic transplant, drug-induced immune suppres-
sion in solid-organ transplant or cytotoxic therapy, and
HIV-infected patients) were excluded. The institution’s in-
ternal review board approved the study (Comite Etic d’In-
vestigacio Clinica, registry number 2009/5427), and
written informed consent was obtained from patients or
their next of kin.
Definition of pneumonia
Clinical suspicion of pneumonia was based on clinical cri-
teria as suggested in the guidelines [1, 5, 19]: (1) new or
progressive radiologic pulmonary infiltrate, (2) together
with at least two of the following: temperature > 38 °C or
< 36 °C, leukocytosis > 12,000/mm3 or leukopenia < 4000/
mm3, or purulent respiratory secretions. HAP was defined
in patients who developed pneumonia after 48 h of
hospitalization when not receiving invasive mechanical
ventilation (iMV) [1, 20].
Data collection
All relevant data were collected upon ICU admission
and at the onset of pneumonia from the medical records
and bedside flow charts, including clinical, laboratory,
radiological, and microbiological information. Patients’
follow-up was extended to death, to hospital discharge,
or up to 90 days after the diagnosis of pneumonia. The
assessment of severity included the Acute Physiology
and Chronic Health Evaluation (APACHE)-II [21] and
the Sequential Organ Failure Assessment (SOFA) score
[22], calculated upon ICU admission and at HAP
diagnosis.
Microbiologic assessment and methods
We tried to assess all patients upon clinical diagnosis of
HAP, aiming to establish a microbiological diagnosis.
Lower respiratory airway samples that could be collected
for quantitative bacterial and fungal cultures were (1)
sputum, (2) endotracheal aspirate (EAT), (3) bronchial
aspirate through a fiberoptic-bronchoscopy (FBAS), and
(4) bronchoalveolar lavage (BAL), blinded or through a
fiberoptic-bronchoscopy. Only samples of sputum or tra-
cheal aspirates of high quality (i.e. < 10 squamous cells
and > 25 leukocytes per optical microscopy field) were
processed for culture. Additionally, blood cultures (rec-
ommended to all patients) and pleural fluid (if a pleural
puncture was indicated) could be collected, as well as
urinary antigens of Legionella sp. and Streptococcus
pneumoniae (mainly recommended for early-onset
HAP). Pathogen identification and susceptibility testing
were performed by standard methods [23]. Microbio-
logical diagnosis was defined by the presence of at least
one potentially pathogenic microorganism (PPM) in re-
spiratory samples above predefined thresholds (sputum,
EAT, FBAS > 105 colony-forming units/mL or BAL >
104, or any count if the patient was receiving a new sys-
temic antibiotic treatment). Blood cultures were consid-
ered positive if an alternative cause of bacteremia was
ruled out [23].
Polymicrobial pneumonia was defined when more
than one PPM was identified as causative agents. The
initial empiric antimicrobial treatment was chosen fol-
lowing a local adaptation of the 2005 ATS/IDSA guide-
lines [5], based on the most frequently isolated
pathogens and their patterns of antimicrobial sensitivity
at our institution. The empiric antimicrobial treatment
was considered appropriate when the isolated pathogens
were susceptible in vitro to at least one of the antimicro-
bials administered. Multi-drug-resistant pathogens were
defined based on consensus definition [24].
Antibiotic de-escalation was considered when physi-
cians changed the antibiotic regimen to a narrower
spectrum regimen, stopped the coverage for a class of
pathogens (e.g., Staphylococcus aureus), or reduced the
number of antibiotics prescribed [25–27]. Escalation was
considered when physicians introduced a new regimen
with broader coverage. We further divided the patients
whom the empiric antibiotic scheme was maintained in
those that no change was done, and in those whom an
additional antibiotic was added to the empiric regimen.
Statistical analysis
To analyze the diagnostic yield of the sampling method,
we divided HAP patients into those who were
Ranzani et al. Critical Care           (2019) 23:51 Page 2 of 11
subsequently intubated and those who were not, since in
patients under iMV, the airway is easy to reach for lower
respiratory sampling collection. We also compared pa-
tients who received a fiberoptic-bronchoscopy when
undergoing or not undergoing iMV.
Data were presented as numbers (proportions) and as
means ± SD or medians [p25-p75]. Qualitative or cat-
egorical variables were compared with the chi-square
test or Fisher’s exact test, as appropriate. Quantitative
continuous variables were compared using the unpaired
Student t test, one-way ANOVA, and Mann-Whitney or
Kruskal Wallis tests as appropriate. All tests were
two-sided, and Stata 13.1 was used for all analyses.
Results
Of the 488 patients enrolled during the cohort period, we ex-
cluded 288 (59%) patients who were diagnosed with pneu-
monia while receiving mechanical ventilation (i.e., VAP).
Therefore, we analyzed 200 (41%) patients with HAP.
Patient characteristics
The main clinical characteristics upon ICU admission
and at onset of HAP are shown in Table 1. Mean age
was 66 years, and there was a high proportion of males.
Approximately one third had a chronic comorbidity.
The main cause of ICU admission was acute respiratory
failure followed by shock and postoperative status. One
hundred twenty-two patients (61%) required iMV after
the onset of HAP (Fig. 1), and 72 (59%) intubations oc-
curred within 24 h of diagnosis. The median ICU length
of stay was 13 [7–26] days, and 85 (43%) patients died in
the hospital. Patients who needed iMV after HAP diag-
nosis presented higher hospital mortality than those who
did not [62 (51%) vs. 23 (30%), p = 0.003].
Diagnostic approach
In the 200 patients with HAP, 89% underwent at least
two methods for microbiological assessment (median 3
[2–4] methods). Patients who required iMV had a higher
number of microbiological assessments than those who
did not (3 [2–4] vs. 2 [2, 3], p < 0.001, respectively). Re-
spiratory samples were obtained in 186 (93%) patients,
and at least two respiratory methods were applied in
40%. Blood cultures (79%), urinary antigen (48%), and
FBAS (47%) were the methods most commonly applied
to microbiological assessment (Fig. 2, Table 2, and Add-
itional file 1: Table S1). Sputum and BAL were per-
formed in almost one third of patients, while 18% had
pleural liquid cultures. Sputum, EAT, FBAS, and BAL
were the methods that obtained the highest proportions
of positivity (Fig. 2, Table 2, and Additional file 1: Table
S1), followed by pleural liquid, blood culture, and urin-
ary antigen testing.




Age (year), mean SD 66 ± 12
Sex (male), n (%) 137 (69%)
Smoker (current or past), n (%) 105 (53%)
Alcohol abuse (current or past), n (%) 52 (26%)
Comorbid Conditions, n (%)
Chronic heart disease 76 (38%)
Chronic lung disease 73 (37%)
Solid cancer 55 (28%)
Diabetes 48 (24%)
Chronic hepatic disease 48 (24%)
Chronic renal failure 24 (12%)
Severity at ICU admission
APACHE II at ICU admission, mean SD 15.8 ± 6
SOFA at ICU admission, median [p25-p75] 6 [4–9]
Reason of ICU admission, n (%)
Hypoxemic respiratory failure 57 (29%)
Hypercapnic respiratory failure 32 (16%)
Shock 28 (14%)
Postoperative 42 (21%)
Non-surgical abdominal condition 15 (7%)
Altered mental status 8 (4%)
Multiple trauma 3 (2%)
Other 15 (7%)
Severity Scores at diagnosis
APACHE II Score at HAP, mean SD 16.3 ± 5
SOFA Score at HAP, median [p25-p75] 6 [4–9]
Features at diagnosis
Temperature, mean SD 36.6 ± 1
Leukocytes, mean SD 14,495 ± 7224
PaO2/FiO2, mean SD 178 ± 79
Bilateral infiltrates, n (%) 66 (33%)
Multilobar infiltrates, n (%) 109 (55%)
Pleural effusion, n (%) 86 (44%)
ARDS at pneumonia diagnosis, n (%) 27 (14%)
Previous use of antibiotic, n (%)* 151 (76%)
Outcomes
ICU length-of-stay, days median [p25-p75] 13 [7–26]
Hospital length-of-stay, days median [p25-p75] 37 [22–61]
ICU mortality, n (%) 62 (31%)
ARDS Acute respiratory distress syndrome, APACHE II Acute Physiology and
Chronic Health Evaluation, SOFA score Sequential Organ Failure
Assessment score
*Not necessarily concomitant to sample collection
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Fig. 1 Time flow-chart for the microbiological assessments performed in 200 patients with hospital-acquired pneumonia. BAL bronchoalveolar
lavage, EAT endotracheal aspirate, FBS fiberoptic-bronchoscopy, FBAS fiberoptic-bronchoscopy aspirate, HAP hospital-acquired pneumonia, iMV
invasive mechanical ventilation
A B C
Fig. 2 Sampling methods and corresponding positivity in a whole cohort, b patients not requiring invasive mechanical ventilation, and c patients
requiring invasive mechanical ventilation. BAL bronchoalveolar lavage, EAT endotracheal aspirate, FBAS fiberoptic-bronchoscopy aspirate, iMV
invasive mechanical ventilation. *Percentage among those in whom the method was performed
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Microbiological diagnosis was possible in 99 (50%) pa-
tients. Patients who required iMV had a higher propor-
tion of microbiological diagnosis than those who did not
(56 vs. 40%, P = 0.027, Table 2). Thirty-eight (19%) pa-
tients received a new antibiotic before sample collection
and had a lower proportion of microbiological diagnosis
than those who did not (34 vs. 53%, p = 0.036). Overall,
the most common pathogens identified were
Gram-negative non-fermenting bacteria (39/99, 39%),
followed by Staphylococcus aureus (24/99, 24%) and
Gram-negative enteric bacteria (24/99, 24%). The preva-
lence of polymicrobial HAP was 17% (17/99), while 40%
had a MDR pathogen. The distribution of causative
pathogens was similar in those who required iMV and
those who did not (Table 2). The cross-tabulation of dif-
ferent methods for microbiological assessment and their
agreement on the same pathogen, when positive, are
shown in Fig. 3. The average overall agreement was 80%










Definitive causative pathogen 99 (50%) 31 (40%) 68 (56%) 0.027
Gram negative non-fermenting bacteria 39/99 (39%) 11/31 (35%) 28/68 (41%) 0.59
Pseudomonas aeruginosa 30/99 (30%) 10/31 (32%) 20/68 (29%) 0.78
S. aureus 24/99 (24%) 6/31 (19%) 18/68 (27%) 0.44
MSSA 15/99 (15%) 4/31 (13%) 11/68 (16%) 0.77
MRSA 9/99 (9%) 2/31 (7%) 7/68 (10%) 0.72
Gram negative enteric bacteria 24/99 (24%) 8/31 (26%) 16/68 (24%) 0.81
Community pathogens (S. pneumococcus, Haemophylus influenzae) 9/99 (9%) 3/31 (10%) 6/68 (9%) > 0.99
Virus 3/99 (3%) – 3/68 (4%) 0.55
Other 9/99 (9%) 1/31 (3%) 8/68 (12%) 0.27
Polymicrobial 17/99 (17%) 3/31 (10%) 14/68 (21%) 0.182
Multi-drug resistant 40/99 (40%) 12/31 (39%) 28/68 (41%) 0.82
Microbiological diagnosis by
Sputum 23/99 (23%) 11/31 (36%) 12/68 (18%) 0.051
EAT 27/99 (27%) – 27/68 (40%) < 0.001
FBAS 46/99 (47%) 15/31 (48%) 31/68 (46%) 0.80
BAL 18/99 (18%) 2/31 (7%) 16/68 (24%) 0.041
Pleural fluid 6/99 (6%) – 6/68 (9%) 0.051
Urinary antigen 5/99 (5%) 3/31 (10%) 2/68 (3%) 0.175
Blood culture 14/99 (14%) 4/31 (13%) 10/68 (15%) > 0.99
Microbiological diagnosis by
1 method 69/99 (70%) 27/31 (87%) 42/68 (62%) 0.015
2 methods 20/99 (20%) 4/31 (13%) 16/68 (23%)
3 methods 10/99 (10%) – 10/68 (15%)
Microbiological diagnosis uniquely defined by 1 method
Sputum 10/69 (15%) 9/27 (33%) 1/42 (2%) 0.001
EAT 16/69 (23%) – 16/42 (38%) < 0.001
FBAS 29/69 (42%) 12/27 (44%) 17/42 (41%) 0.81
BAL 6/69 (9%) – 6/42 (14%) 0.075
Pleural fluid – – – –
Urinary antigen 3/69 (4%) 3/27 (11%) – 0.056
Blood culture 5/69 (7%) 3/27 (11%) 2/42 (5%) 0.37
BAL bronchoalveolar lavage, EAT endotracheal aspirate, FBS fiberoptic bronchoscopy, FBAS fiberoptic-bronchoscopy aspirate, HAP hospital-acquired pneumonia,
iMV invasive mechanical ventilation
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(40/50). Indeed, there was 85% agreement for sputum
with other respiratory samples (11/13), 80% for EAT (8/
10), 81% for FBAS (13/16), and 91% for BAL (10/11).
The majority of microbiological diagnoses were deter-
mined by only one method (69/99, 70%), with differ-
ences among those who required iMV and those who
did not (p = 0.015). FBAS was the only method respon-
sible for the diagnosis of 42% (29/69) patients, followed
by EAT (23%), sputum (15%), BAL (9%), and blood cul-
ture (7%).
One hundred twenty-five (63%) patients underwent in-
vasive sampling, of whom 78 (39%) were applied
fiberoptic-bronchoscopy while not receiving iMV (Fig. 1).
Patients who required iMV after invasive sampling were
more severe at HAP diagnosis (Additional file 2: Table
S2). There was no significant difference in the propor-
tion of final microbiological diagnoses when stratifying
by fiberoptic-bronchoscopy when receiving or not re-
ceiving iMV (p = 0.112); however, among the patients
who did not require iMV, the rate of microbiological
diagnosis was 10% higher (95% CI, − 12 to 32%) in those
who underwent fiberoptic-bronchoscopy. When stratify-
ing patients according to non-invasive (sputum and
EAT) or invasive (FBAS and BAL) respiratory methods,
we observed higher proportions of microbiological diag-
noses in those who underwent at least one invasive
method (56 vs. 39%, risk difference 17%, 95% CI, 3–31%,
p = 0.018), mainly due to those who required iMV.
Antibiotic management and duration
The majority of patients received the initial antibiotic
regimen in accordance with the 2005 ATS/IDSA guide-
lines; empiric antibiotic treatment was adequate in 71%
(70/99 patients) (Table 3). Patients who had a microbio-
logical diagnosis more frequently changed their empir-
ical antibiotic regimen (P = 0.006), driven by de-
escalation (30 vs. 8%). However, patients who had a
microbiological diagnosis also received longer total anti-
biotics duration than patients without microbiological
diagnosis, although similar duration when considered
only the empiric antibiotic scheme.
Discussion
We could achieve microbiological diagnosis in 50% of
200 patients with HAP occurring during ICU stay using
an intensive diagnostic approach. Upon HAP clinical
diagnosis, around 40% of patients underwent fiberoptic-
bronchoscopy while not receiving iMV. Finally, invasive
respiratory sampling was associated with a higher rate of
microbiological diagnosis.
Recent recommendations from the FDA recognized
that there are three different types of nosocomial pneu-
monia with different all-cause mortality rates:
non-ventilated HAP, ventilated HAP, and VAP [28, 29].
Interestingly, the highest mortality has been observed in
patients with HAP who subsequently required iMV. In a
recent summary of these recommendations, Talbot
A B
Fig. 3 Distribution and agreement of different sampling methods (a cross-tabulation of different methods; b agreement on the same pathogen
when both methods were positive). Square colors divided as dark blue for agreement ≥ 75%, blue for agreement between ≥ 50 and < 75%, light
blue for agreement between ≥ 25 and < 50%, and grey for agreement < 25%. BAL bronchoalveolar lavage, EAT endotracheal aspirate, FBAS
fiberoptic-bronchoscopy aspirate
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highlighted the necessity to have information about sam-
pling and causative pathogens in the non-VAP popula-
tion [28]. Our study is the first one to provide this
information in a detailed way, which can be very useful
for empirical treatment adequacy and for future RCT
studying new antibiotics.
Being able to achieve a microbiological diagnosis in
HAP has important consequences for patient care. First,
it can support the suspicion of infection in a new lung
infiltrate appearing concomitantly with fever in a critic-
ally ill patient, a frequent challenge for the attending
physician [30]. Second, it makes possible to target the
empiric antibiotic scheme more accurately, thus increas-
ing the likelihood of clinical cure, preventing the selec-
tion pressure to further resistances, and reducing costs
and unnecessary side effects [1]. Our findings corrobo-
rated two important phenomena reported elsewhere: (1)
patients with microbiological diagnosis more commonly
had an adaptation in their empiric antibiotic regimen
and (2) patients without microbiological diagnosis re-
ceived shorter total antibiotic treatment [31, 32]. Al-
though a microbiological diagnosis is central in all
infections both for epidemiological studies and for bed-
side care by clinicians, it becomes fundamental for
hospital-acquired infections, because of higher probabil-
ity of resistant pathogens, greater amount of antibiotic
use and side effects, and associated costs.
Interestingly, one third of patients underwent sputum col-
lection, which was positive in 34% of cases after ensuring
sample quality and performing quantitative cultures. Very
few data are available on the applicability of sputum in HAP
[1, 16, 17]. In our experience, this non-invasive diagnostic
method should be encouraged, as it already is for
community-acquired pneumonia [33]. Indeed, when only
one diagnostic method was positive, 15% of microbiologic
confirmations were due to sputum, and in patients who were
not subsequently intubated, this proportion was even higher
(33%). Despite the limited numbers of patients allowing for
pair-wise comparisons between methods, we observed a
good agreement on retrieving the same pathogen (80% on
average). As expected it was higher for invasive methods
(FBAS vs. BAL, 86% of agreement). In our protocol, we tried
to obtain as much as possible respiratory samples to increase
the likelihood of identifying a causative pathogen, and the
good agreement observed is reassuring. When two methods
were discordant, respecting the sample quality check and
cutoff values, clinicians interpreted the episode as polymicro-
bial and treated both pathogens, which is sound in critically
ill patients. Taking different respiratory samples also in-
creases the risk of false positives (i.e., colonization). We could
not evaluate the actual impact that discordance between
methods would have in clinician’s decision in a scenario
where there would be a hierarchy between methods, for
instance.
In this observational study, patients assessed with an
invasive diagnostic method had higher rates of microbio-
logical diagnosis. Although there is evidence that inva-
sive and non-invasive approaches have a comparable
impact on patient-centered outcomes in VAP [1], no evi-
dence is available for HAP in immunocompetent pa-
tients [1]. In fact, the 2016 IDSA/ATS guidelines
propose non-invasive respiratory sampling in HAP, al-
though the panel agreed that there may be factors that
prompt clinicians to consider invasive sampling [1]. In a
small single-center randomized trial aiming to compare
invasive and non-invasive approaches in patients with
HAP outside the ICU, Herer et al. found that clinical
cure rates at 28 days were similar between groups; how-
ever, the study was rather exploratory in nature, with
several limitations and a small sample size [18].
Because of the barriers to obtaining lower respiratory
tract samples in HAP, we cannot straightforwardly ex-
trapolate the evidence from VAP to HAP. Indeed, an inva-
sive approach might have higher clinical utility in HAP,
particularly in those patients who will not require iMV. A
key point when discussing invasive vs. non-invasive tactics
in HAP is the feasibility and safety of performing a
fiberoptic-bronchoscopy. Several reports show that
fiberoptic-bronchoscopy, followed by BAL or mini-BAL,
can be conducted in patients with acute respiratory failure
and community- and healthcare-acquired pneumonia and
is even safer when non-invasive ventilation and high-flow
oxygen therapy are applied [34–39]. In a landmark trial,
Azoulay et al. showed that an invasive approach had a
similar rate of intubation to a non-invasive approach in
non-ventilated, immunosuppressed patients with acute re-
spiratory failure [40].
Invasive mechanical ventilation after HAP diagnosis was
commonly needed in our population of critically ill patients,
being applied 60% of the time within 24 h. Despite its clear
implications for prognosis, having an endotracheal tube
vastly facilitates access to a lower respiratory tract sample
using either invasive or non-invasive approaches. The abil-
ity to predict which patients will need iMV in the next
hours can help guide clinicians faced with the decision of
performing a prompt fiberoptic-bronchoscopy or postpon-
ing it until after the intubation. The development of a pre-
diction tool is beyond the scope of this study, but we
observed that severity, hypoxemia, and chest X-ray patterns
were associated with intubation after performing a
fiberoptic-bronchoscopy.
Our study has some strengths. We included prospect-
ive cases of HAP acquired during an ICU stay from six
ICUs. Our center also has a comprehensive clinical
decision-making protocol for achieving microbiological
diagnosis in lung infections, which means that our data
are relevant for the description of microbiological diag-
nosis in HAP. Moreover, the causative pathogens
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responsible for HAP in our cohort are similar to those
reported elsewhere, where Gram-negative bacteria have
been implicated in 55% to 85% of HAP cases and
Gram-positive cocci (particularly Staphylococcus aureus)
account for 20% to 30% [7, 9–11, 13, 14, 41], thus in-
creasing the generalizability of our results. In addition,
the results of this study cover an unmet need of know-
ledge (microbiological diagnosis of HAP) highlighted by
the recent IDSA ATS and International guidelines for
HAP and VAP [1, 3].
However, there are several limitations that must be
highlighted. First, our study is retrospective and
single-center and, although we collected data from six
ICUs with different profiles (from general medical to re-
spiratory and liver units), the single-center characteristic
decreases the generalizability of our findings. Second,
our study is observational and allowed us for a reliable
description of real-life diagnostic methods approaches
for achieving microbiological diagnosis in HAP, our pri-
mary objective. However, the crude associations found
for the potential benefit of invasive methods are explora-
tory and not causal; a well-designed, controlled random-
ized trial is now warranted to define the management of
HAP regarding the use of invasive or non-invasive
methods. Third, we could recruit 200 patients, which
limited our ability to explore subgroups and pair-wise
comparisons between different methods, but to the best
of our knowledge, this is one of the first and largest
studies reporting all these different diagnostic methods
in critically ill nonventilated HAP [42]. Third, we could
not achieve 100% of respiratory samples in the cohort;
however, we believe that 93% represents a very high pro-
portion of patients, considering the daily care in an ICU.
Fourth, our population comprised critically ill patients,
who commonly require iMV, and our results may not be
applicable to patients outside the ICU. Fifth, we did not
have a “gold standard” to confirm that the pathogen
identified was responsible for the infection and not only
colonizing the airways, a potential limitation particularly
for sputum cultures. To limit the number of false posi-
tives, we used the most standard quality assessment to
accept only lower airway representative samples. Sixth,
at the time the current study was conducted, our center
did not have routine access to rapid diagnostic methods
because they were not standard of care, but these
methods have been shown to be promising tools for
pathogen identification in HAP [43]. The performance
of rapid diagnostic methods in nonventilated HAP, util-
izing different sampling strategies, must be evaluated
and could produce different results compared to our
findings. Particularly, rapid diagnostic methods could in-
crease the sensitivity for pathogen identification in those
patients already receiving a new antibiotic upon sample
collection, a fact that might explain the reason we
achieved only 50% of microbiological diagnosis using
traditional culture methods [44]. Finally, we did not con-
duct a cost-effective analysis [1, 18], which is a key elem-
ent when comparing different respiratory sampling
methods.
Conclusion
In summary, our study raises the point that a compre-
hensive approach might be undertaken for microbio-
logical diagnosis in critically ill nonventilated HAP.
Sputum determined one third of microbiological diagno-
sis in HAP patients who were not subsequently intu-
bated. Invasive methods were associated with higher
rates of microbiological diagnosis; however, this might
be replicated in other populations and through a ran-
domized, well-designed, controlled trial.
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Additional file 2: Table S2. Comparison between patients who did
invasive sampling while receiving or not receiving invasive mechanical
ventilation. Additional data about general characteristics and
microbiological diagnosis between patients who did invasive sampling
methods while receiving or not mechanical ventilation. (PDF 143 kb)
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